Reactions 1512, p15 - 2 Aug 2014

Cetuximab

Dermatologic toxicity: case reportA 65-year-old man developed grade 2 dermatologic toxicity

during treatment with cetuximab [route not stated]. The manhad a medical history of parotid cancer along with multiplelung metastases managed with complete anti-androgenblockade. His subsequent immunohistochemistry evaluationdetected a strong and diffuse epidermal growth factor receptor(EGFR) positivity and he started receiving 2nd line biologictherapy with cetuximab 250 mg/m2 weekly for 10 months anddeveloped grade 2 dermatologic toxicity [duration of treatmentto reaction onset and outcome not stated].

Author comment: "The patient received weeklyCetuximab (250 mg/m2) for 10 months achieving a minimalresponse with a [grade 2] dermatologic toxicity"Airoldi M, et al. Efficacy of a second biologic treatment in androgen receptor-positive (AR+) recurrent/metastatic salivary duct carcinoma (RMSDC). Journal ofClinical Oncology 32 (Suppl.): No. 15, 20 May 2014. Available from: URL: http://meeting.ascopubs.org/cgi/content/abstract/32/15_suppl/e17055 [abstract] -Italy 803106493

1

Reactions 2 Aug 2014 No. 15120114-9954/14/1512-0001/$14.95 Adis © 2014 Springer International Publishing AG. All rights reserved